This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clincial Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
There are currently 24 open trials.
In 107 locations
What is a Clinical Trial?
There are currently 24 open trials
- MUK eleven
- Myeloma XII (ACCoRd)
- Venetoclax in combination with bortezomib and dexamethasone
- Durvalumab and daratumumab for relapsed and refractory myeloma patients (FUSIONMM-003 trial)
- Pembrolizumab, Revlimid and dexamethasone for newly diagnosed myeloma patients (KEYNOTE-185 trial)
- Ixazomib and dexamethasone for relapsed or refractory AL amyloidosis patients (TOURMALINE-AL1)
- NEOD001 for previously treated AL amyloidosis patients (PRONTO trial)
- NEOD001 for newly diagnosed AL amyloidosis (VITAL trial)
- ACP-196 with or without dexamethasone
- Buparlisib in combination with bortezomib (BUBBLE trial)
- Early access treatment with daratumumab
- DTP3 in myeloma
- MUK seven
- Carfilzomib in combination with dexamethasone (ARROW trial)
- MUK Eight
- Ixazomib maintenance treatment for older and/or less fit myeloma patients (TOURMALINE MM4 trial)
- Daratumumab, Revlimid and dexamethasone for newly diagnosed myeloma patients
- Pomalidomide, bortezomib and dexamathasone (OPTIMISMM trial)
- Daratumumab combination for newly diagnosed myeloma patients
- Carfilzomib for newly diagnosed patients prior to stem cell transplant (CARDAMON trial)
- Bendamustine combination for newly diagnosed myeloma patients with kidney impairment (OPTIMAL trial)
- RO5126766 trial
- GSK2857916 trial
- GSK525762 trial
Trial Title:
MUK eleven
Treatments:
Reolysin® (Pelareorep)
Lenalidomide (Revlimid)
Pomalidomide (Imnovid®)
Myeloma stage:
Relapsed, Refractory
Trial phase:
I
Summary:
This trial is investigating whether Reolysin, a type of viral therapy, can halt relapse in patients who are being treated with lenalidomide (Revlimid®) or pomalidomide (Imnovid®). It is specifically looking to identify the best dose of Reolysin to use.
Locations:
St James' Hospital, Leeds
Who can enter the study?:
- Patients who are on currently being treated with lenalidomide or pomalidomide (with or without steroids) but who are showing signs of relapse
- Patients cannot enter if they have non-secretory myeloma i.e. do not produce paraproteins or free light chains
What's involved?:
Depending on their current treatment, patients will continue to receive either lenalidomide (10mg dose or current dose if lower than 10mg) or pomalidomide (1mg or current dose if lower than 1mg) on days 1-21 of a 28 day cycle. Patients who are also on steroid treatment must stop taking it at least 48 hours before starting their first Reolysin treatment.
Reolysin is given as a one hour intravenous (into the vein) infusion on days 1, 8, 15 and 22.
Treatment is continued until there are signs the myeloma is progressing or because of other reasons.
Patients are required to visit the outpatient clinic for regular blood test and checkups.
Clinical Information
(for Medical Professionals):
This trial is aiming to determine the maximum tolerated dose of Reolysin that can be given in combination with lenalidomide or pomalidomide in two separate cohorts of relapsed and/or refractory myeloma patients. It is also investigating the safety, side-effects and effectiveness of the treatment combinations.
For more information, click here.
Find out more: